175696-70-5

Basic information

• Product Name: (3-PYRROLIDIN-1-YLPHENYL)METHYLAMINE
• Synonyms: 3-PYRROLIDINOBENZYLAMINE;(3-PYRROLIDIN-1-YLPHENYL)METHYLAMINE;3-(PYRROLIDIN-1-YL)BENZYLAMINE;CHEMBRDG-BB 4014845;3-(Pyrrolidin-1-yl)benzylamine 90%;(3-(Pyrrolidin-1-yl)phenyl)MethanaMine;[3-(Pyrrolidin-1-yl)phenyl]methylamine 90%;3-(Pyrrolidin-1-yl)benzylamine, 1-[3-(Aminomethyl)phenyl]pyrrolidine
• CAS NO: 175696-70-5
• Molecular Formula: C₁₁H₁₆N₂
• Molecular Weight: 176.26
• Mol File: 175696-70-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 328.1 °C at 760 mmHg
• Flash Point: 132.6 °C
• Appearance: /
• Density: 1.075 g/cm³
• Vapor Pressure: 0.000194mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: 2-8°C
• PKA: 9.27±0.10(Predicted)
• CAS DataBase Reference: (3-PYRROLIDIN-1-YLPHENYL)METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (3-PYRROLIDIN-1-YLPHENYL)METHYLAMINE(175696-70-5)
• EPA Substance Registry System: (3-PYRROLIDIN-1-YLPHENYL)METHYLAMINE(175696-70-5)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 175696-70-5(Hazardous Substances Data)

Usage

General Description

"(3-Pyrrolidin-1-ylphenyl)methylamine" is a chemical with the molecular formula C13H17N and a molecular weight of 183.29 g/mol. It is a phenylmethylamine compound that contains a pyrrolidinyl group. This chemical is an amine, which means it contains a nitrogen atom bonded to at least one hydrogen atom. Its specific uses and properties are not widely documented, but phenylmethylamine compounds are often associated with effects on the central nervous system and may have potential applications in pharmaceuticals, organic synthesis, and research. Additional information would be needed to fully understand the potential uses and impacts of "(3-Pyrrolidin-1-ylphenyl)methylamine".

InChI:InChI=1/C11H16N2/c12-9-10-4-3-5-11(8-10)13-6-1-2-7-13/h3-5,8H,1-2,6-7,9,12H2

Upstream product

• 828242-06-4 tert-butyl N-[(3-pyrrolidin-1-ylphenyl)methyl]carbamate 
• 263351-43-5 tert-butyl N-[(3-iodophenyl)methyl]carbamate 
• 2237-30-1 m-cyanoaniline 
• 175696-73-8 3-(pyrrolidin-1-yl)benzonitrile 
• 766-84-7 3-chloro-benzonitrile 

Downstream Products

• 1590397-58-2 2-(4-fluoro-N-isopropylphenylsulfonamido)-N-(3-(pyrrolidin-1-yl)benzyl)acetamide 
• 1092067-86-1 C₃₄H₄₀Cl₂N₆O₂ 
• 1028338-17-1 4-chloro-6-(3-pyrrolidin-1-yl-benzylamino)-2H-phthalazin-1-one 
• 828242-06-4 tert-butyl N-[(3-pyrrolidin-1-ylphenyl)methyl]carbamate 

Relevant articles and documents

A State-of-the-Art Heterogeneous Catalyst for Efficient and General Nitrile Hydrogenation

Cobalt-doped hybrid materials consisting of metal oxides and carbon derived from chitin were prepared, characterized and tested for industrially relevant nitrile hydrogenations. The optimal catalyst supported onto MgO showed, after pyrolysis at 700 °C, magnesium oxide nanocubes decorated with carbon-enveloped Co nanoparticles. This special structure allows for the selective hydrogenation of diverse and demanding nitriles to the corresponding primary amines under mild conditions (e.g. 70 °C, 20 bar H2). The advantage of this novel catalytic material is showcased for industrially important substrates, including adipodinitrile, picolinonitrile, and fatty acid nitriles. Notably, the developed system outperformed all other tested commercial catalysts, for example, Raney Nickel and even noble-metal-based systems in these transformations.

ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS

Compounds represented by Formula (I) which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R', R